Solar Biotech acquires VC-backed digital biology platform Noblegen

• Noblegen will now operate under the name Solar Biotech Canada
• Solar Biotech Canada’s new facility comprises a biomanufacturing hub with a nominal capacity of over 160,000 liters of upstream precision fermentation and downstream processing equipment
• In 2019, Noblegen secured C$25 million in a Series B financing

Solar Biotech, a Norton, Virginia-based provider of sustainable and scalable biomanufacturing solutions, has acquired Noblegen, an advanced digital biology company with headquarters in Peterborough, Ontario. No financial terms were disclosed.

Noblegen will now operate under the name Solar Biotech Canada, continuing as the organization’s food-grade-certified biomanufacturing and research and development hub in Canada.

“This is a significant step forward for Solar Biotech and its industrial partners since it immediately brings online much-needed capacity and expertise in the biomanufacturing industry,” said Alex Berlin, CEO of Solar Biotech, and the newly appointed chairman of Solar Biotech Canada, in a statement. “We are bringing together two innovative companies with complementary intellectual property portfolios and sector experience that will help us make a lasting impact on the world.”

Solar Biotech Canada’s new biomanufacturing facility in Peterborough comprises a fully-equipped biomanufacturing hub with a nominal capacity of over 160,000 liters of upstream precision fermentation and downstream processing equipment.

Noblegen was previously backed by venture capital investors. In 2019, the company secured C$25 million in a Series B financing led by Richardson Ventures, an affiliate of Canadian holding company James Richardson & Sons, and the clean technology practice of Business Development Bank of Canada.